Background
==========

Tumor vasculature, a crucial feature in cancer development and progression, is based on angiogenesis and vasculogenesis driven by VEGF signalings \[[@B1]-[@B3]\] but also on tumor endothelial transdifferentiation and vascular mimicry \[[@B4]\]. The VEGFR1 and VEGFR2 tyrosine kinase receptors are primarily expressed by endothelial cells. Recent studies, however, suggest that tumor-derived VEGF provides not only paracrine survival cues for endothelial cells, but may also autocrine processes in tumor cells expressing VEGFRs and play a role in tumor resistance to existing anti-angiogenic therapies \[[@B5]-[@B7]\].

Growth of patient tumor fragments into immunodeficient mice allows an accurate depiction of human tumor biological characteristics and are considered to represent the heterogeneity of human cancers (for review \[[@B8]\]). These patient-derived tumor xenografts (PDX) are greatly helpful to evaluate fundamental issues in cancer and chemosensitivity response, including characteristics of angiogenesis, tumor-stroma interactions and response to antiangiogenic therapies. As real-time quantitative RT-PCR is highly specific, species-specific primer sets can allow to discriminating between mouse/stromal and human/cancer gene expression in PDX models.

To obtain further insight into tumor vascularization and VEGFR expression by cancer and non-tumor cells, we used real-time qRT-PCR to quantify species-specific mRNAs of *PECAM1/CD31, ENG/CD105, FLT1/VEGFR1, KDR/VEGFR2* and *VEGFA* genes in a large series of 150 xenografts from different tumor types. We also validated clinical relevance of species-specific PCR assays for *in vivo* evaluation of anti-angiogenesis therapy in two non small cell lung carcinoma models. We showed human *PECAM1/CD31 and ENG/CD105* expression in all tumor types, supporting existence of human tumor endothelial cells in all tumor types. In addition, the *VEGFR* expression profiles led to involvement of both stromal and tumoral autocrine VEGFA-VEGFR1/2 signalings in tumors.

Results and discussion
======================

First, the proportion of mouse cells was estimated in a panel of 8 different PDX types, using a real-time qRT-PCR assay combining primers specific for mouse *Tbp* RNA and primers able to amplify a common sequence on both human and mouse *TBP* transcripts. (Additional file [1](#S1){ref-type="supplementary-material"}: Table S1). As this gene encoding the TATA box-binding protein is a robust house-keeping gene \[[@B9]\] with similar amplification efficiency for the 2 primer sets, the ratio reflects the percentage of mouse cells within xenograft as validated in a standard curve of mouse and human cDNA mixtures (data not shown).

In an initial series of 157 human xenografts, the proportion of mouse cells was 100% in 7 tumors. These 7 tumor samples probably originated from spontaneous mouse lymphoma, frequently observed in immunodeficient mice \[[@B10]\].

In the 150 other xenografts, mouse host cells were found in all specimens with a median proportion of mouse cells of 9%, ranged between 3.3% in SCLC and 20% in NSCLC (*p* \< 0.05, Table [1](#T1){ref-type="table"}). To note, all the xenografts used here, have been passaged at least 5 times in mice, leading to a replacement of human stroma by mouse components \[[@B8]\].

###### 

Normalized gene expression for each of the 150 PDX samples, classified by tumor type (noted in bold)

  **Sample nature**                     **Derived from primary tumor or metastatis**   **% of mouse cells**   **PECAM1**   **ENG**      **VEGFR1**   **VEGFR2**   **VEGFA**   **% of*mVegfa*vs human + mouse VEGFA transcripts**                                                     
  ------------------------------------- ---------------------------------------------- ---------------------- ------------ ------------ ------------ ------------ ----------- ---------------------------------------------------- ----------- ----------- ------------- ----------- ----------
  Pure human control                                                                   0%                     1265         0            796          0            2610        0                                                    157         0           287           0            
  Pure mouse control                                                                   100%                   0            1176         0            736          0           303                                                  0           879         0             790          
  **Colorectal carcinoma PDX**                                                                                                                                                                                                                                                        
  CRC\#1                                Primary                                        11%                    0            894          2            492          23          453                                                  0           405         4010          212         5%
  CRC\#2                                Primary                                        5%                     0            917          3            398          9           383                                                  0           309         4912          51          1%
  CRC\#3                                Metastasis                                     21%                    1            2380         34           893          14          843                                                  0           803         4642          628         12%
  CRC\#4                                Primary                                        17%                    0            836          \<1          285          0           368                                                  0           299         2876          302         10%
  CRC\#5                                Metastasis                                     8%                     0            813          0            492          3           337                                                  0           374         3552          109         3%
  CRC\#6                                Primary                                        9%                     46           458          217          326          77          196                                                  \<1         176         1866          84          4%
  CRC\#7                                Metastasis                                     8%                     17           553          27           272          65          292                                                  0           210         5230          251         5%
  CRC\#8                                Primary                                        14%                    0            1193         469          614          3           349                                                  0           689         2999          92          3%
  CRC\#9                                Primary                                        8%                     0            967          8            550          3           475                                                  0           379         7973          204         2%
  CRC\#10                               Primary                                        10%                    0            733          \<1          409          176         246                                                  0           284         3463          124         3%
  CRC\#11                               Metastasis                                     9%                     1            1083         \<1          481          300         567                                                  0           410         5461          135         2%
  CRC\#12                               Metastasis                                     4%                     48           479          0            182          26          274                                                  0           230         4937          106         2%
  CRC\#13                               Metastasis                                     4%                     3            356          5            135          289         163                                                  0           168         3606          145         4%
  CRC\#14                               Primary                                        2%                     \<1          260          7            139          305         119                                                  0           143         5085          76          1%
  CRC\#15                               Primary                                        17%                    \<1          1287         \<1          715          51          530                                                  0           419         6541          311         5%
  CRC\#16                               Metastasis                                     5%                     \<1          477          44           237          89          197                                                  0           219         3406          196         5%
  CRC\#17                               Primary                                        17%                    21           1067         49           539          42          382                                                  0           323         3674          555         13%
  CRC\#18                               Primary                                        14%                    4            1078         81           550          33          370                                                  \<1         356         2016          262         12%
  CRC\#19                               Primary                                        4%                     3            288          \<1          162          \<1         120                                                  0           135         4258          111         3%
  CRC\#20                               Metastasis                                     22%                    4            1580         19           754          10          584                                                  \<1         684         5604          391         7%
  CRC\#21                               Metastasis                                     17%                    10           1336         373          749          10          656                                                  0           639         4894          432         8%
  CRC\#22                               Primary                                        18%                    0            2315         322          1081         32          908                                                  0           1262        4671          1244        21%
  CRC\#23                               Metastasis                                     8%                     0            446          407          406          42          202                                                  0           173         2360          155         6%
  CRC\#24                               Primary                                        12%                    0            981          5            581          13          508                                                  0           331         4773          233         5%
  CRC\#25                               Primary                                        5%                     0            622          36           329          0           246                                                  0           285         2643          68          3%
  CRC\#26                               Primary                                        11%                    0            1245         569          480          112         375                                                  0           296         3607          237         6%
  CRC\#27                               Primary                                        14%                    4            1789         3            895          83          682                                                  0           581         3101          891         22%
  CRC\#28                               Carcinosis                                     5%                     3            526          1            326          1           215                                                  0           268         2545          29          1%
  CRC\#29                               Primary                                        11%                    5            1000         2            541          0           364                                                  0           344         3172          391         11%
  CRC\#30                               Primary                                        7%                     0            753          11           332          22          282                                                  0           258         2247          231         9%
  CRC\#31                               Metastasis                                     10%                    \<1          629          1            294          29          241                                                  0           216         2896          210         7%
  CRC\#32                               Primary                                        16%                    0            1073         304          556          28          357                                                  0           469         1731          166         9%
  CRC\#33                               Primary                                        7%                     4            563          \<1          277          7           202                                                  0           218         1253          129         9%
  CRC\#34                               Primary                                        13%                    2            749          379          530          15          306                                                  0           390         4293          157         4%
  CRC\#35                               Primary                                        9%                     0            958          3            484          9           329                                                  0           318         2206          212         9%
  CRC\#36                               Primary                                        21%                    1            991          0            504          32          388                                                  \<1         436         3296          140         4%
  CRC\#37                               Primary                                        19%                    6            1978         16           840          10          391                                                  0           668         2692          182         6%
  CRC\#38                               Primary                                        8%                     2            1114         8            446          2           320                                                  0           367         1889          218         10%
  CRC\#39                               Metastasis                                     12%                    0            1156         478          523          40          366                                                  0           418         4034          214         5%
  CRC\#40                               Primary                                        10%                    \<1          547          94           356          49          199                                                  0           242         1848          142         7%
  CRC\#41                               Carcinosis                                     16%                    0            1552         3            762          7           325                                                  0           457         918           228         20%
  CRC\#42                               Primary                                        31%                    0            1786         \<1          922          94          447                                                  0           599         2710          493         15%
  CRC\#43                               Primary                                        10%                    0            1024         75           459          249         358                                                  2           431         4126          272         6%
  CRC\#44                               Carcinosis                                     15%                    \<1          938          159          565          1           285                                                  0           364         2523          269         10%
  CRC\#45                               Primary                                        12%                    1654         807          512          388          9           215                                                  1           332         969           124         11%
  CRC\#46                               Primary                                        3%                     \<1          412          3            158          2           139                                                  0           168         1865          61          3%
  CRC\#47                               Metastasis                                     6%                     0            521          2            252          \<1         173                                                  0           195         1662          68          4%
  CRC\#48                               Carcinosis                                     10%                    0            843          \<1          417          0           252                                                  0           252         1705          227         12%
  CRC\#49                               Metastasis                                     6%                     1            379          426          274          11          248                                                  0           267         4587          149         3%
  CRC\#50                               Metastasis                                     18%                    31           1697         0            690          23          485                                                  0           421         5271          299         5%
  CRC\#51                               Primary                                        23%                    0            1294         2            662          67          476                                                  0           375         6660          583         8%
  CRC\#52                               Primary                                        38%                    14           3265         398          1126         640         736                                                  0           836         7517          953         11%
  CRC\#53                               Metastasis                                     19%                    0            1657         0            566          15          430                                                  0           430         4014          209         5%
  ***Median***                                                                         ***10.6%***            ***0.7***    ***958***    ***7***      ***484***    ***22***    ***349***                                            ***0***     ***344***   ***3463***    ***210***   ***6%***
  **Ovarian carcinoma PDX**                                                                                                                                                                                                                                                           
  OVC\#1                                Metastasis                                     28%                    42           2575         0            1498         89          1191                                                 159         867         10390         459         4%
  OVC\#2                                Metastasis                                     5%                     4            565          99           350          2           439                                                  34          259         6391          88          1%
  OVC\#3                                Metastasis                                     21%                    1            1427         304          809          69          406                                                  \<1         583         3133          710         18%
  OVC\#4                                Primary                                        6%                     26           709          9            474          0           259                                                  4           272         1528          144         9%
  OVC\#5                                Primary                                        7%                     16           974          81           807          0           802                                                  45          525         14226         95          1%
  OVC\#6                                Primary                                        12%                    3            2052         97           593          19          734                                                  101         528         2628          427         14%
  OVC\#7                                Primary                                        8%                     0            762          4            470          0           270                                                  32          278         6156          266         4%
  OVC\#8                                Primary                                        3%                     2            219          30           119          6           88.8                                                 3           59.2        652           37          5%
  OVC\#9                                Primary                                        8%                     5            1795         2            674          3           518                                                  5           372         2981          184         6%
  OVC\#10                               Primary                                        4%                     1            444          16           288          0           204                                                  22          141         2812          52          2%
  OVC\#11                               Primary                                        20%                    24           1586         54           1036         0           482                                                  2           648         2781          493         15%
  OVC\#12                               Primary                                        13%                    3            877          177          487          0           259                                                  12          285         1720          127         7%
  OVC\#13                               Primary                                        3%                     17           550          207          263          2           196                                                  \<1         224         1134          16          1%
  OVC\#14                               Primary                                        5%                     0            332          \<1          255          21          238                                                  \<1         164         19239         62          0%
  ***Median***                                                                         ***7%***               ***3.7***    ***819***    ***42***     ***480***    ***2***     ***338***                                            ***9***     ***281***   ***2896***    ***136***   ***5%***
  **Glioblastoma PDX**                                                                                                                                                                                                                                                                
  GBM\#1                                Primary                                        8%                     22           712          2051         457          378         559                                                  8           186         18822         241         1%
  GBM\#2                                Primary                                        13%                    1            1351         1143         819          0           799                                                  378         328         17084         296         2%
  GBM\#3                                Primary                                        13%                    1            2372         422          1184         0           1325                                                 0           1237        8452          131         2%
  GBM\#4                                Primary                                        5%                     55           870          321          328          0           503                                                  0           372         5923          78          1%
  GBM\#5                                Primary                                        15%                    0            2600         268          1389         28          1361                                                 294         1413        15443         100         1%
  ***Median***                                                                         ***13%***              ***1.4***    ***1351***   ***422***    ***819***    ***0***     ***799***                                            ***8***     ***372***   ***15443***   ***131***   ***1%***
  **Breast cancer carcinoma PDX**                                                                                                                                                                                                                                                     
  BC\#1                                 Primary                                        2%                     \<1          222          204          113          3           89.4                                                 2           80.7        637           114         15%
  BC\#2                                 Primary                                        8%                     0            666          177          335          19          289                                                  0           162         2997          310         9%
  BC\#3                                 Metastasis                                     10%                    0            679          286          447          5           539                                                  36          259         4961          334         6%
  BC\#4                                 Primary                                        15%                    46           803          91           498          5           366                                                  0           222         3547          447         11%
  BC\#5                                 Primary                                        1%                     \<1          116          0            61.9         33          89.1                                                 4           31.9        15066         77          1%
  BC\#6                                 Metastasis                                     15%                    2            1351         289          634          29          719                                                  150         439         17360         357         2%
  BC\#7                                 Primary                                        22%                    8            1908         442          887          0           1370                                                 0           739         27659         365         1%
  BC\#8                                 Primary                                        6%                     1            810          149          412          18          327                                                  9           280         8360          160         2%
  BC\#9                                 Metastasis                                     10%                    0            713          6            322          13          420                                                  0           279         1020          294         22%
  BC\#10                                Primary                                        6%                     3            370          460          233          0           325                                                  17          134         7447          154         2%
  BC\#11                                Primary                                        6%                     6            993          347          403          29          461                                                  68          325         14282         256         2%
  BC\#12                                Primary                                        8%                     6            1005         466          543          28          664                                                  3           391         25794         363         1%
  BC\#13                                Primary                                        7%                     0            575          92           256          8           266                                                  15          189         6174          132         2%
  BC\#14                                Primary                                        8%                     654          745          45           413          0           279                                                  2           253         3294          71          2%
  BC\#15                                Metastasis                                     11%                    4            912          50           461          1           311                                                  0           286         3458          186         5%
  BC\#16                                Primary                                        2%                     0            199          188          94.6         4           73.6                                                 2           69.7        610           100         14%
  BC\#17                                Primary                                        4%                     13           413          346          134          66          173                                                  32          101         2131          197         8%
  BC\#18                                Primary                                        10%                    \<1          1545         168          743          3           788                                                  11          382         6550          167         2%
  BC\#19                                Metastasis                                     16%                    \<1          2304         167          1188         5           1049                                                 10          771         6004          280         4%
  BC\#20                                Primary                                        17%                    0            1967         340          959          1           709                                                  20          634         11533         357         3%
  BC\#21                                Primary                                        9%                     0            730          334          332          2           476                                                  91          202         8166          520         6%
  BC\#22                                Primary                                        6%                     0            598          451          222          10          334                                                  90          124         5088          264         5%
  BC\#23                                Primary                                        4%                     0            377          331          179          2           195                                                  19          83.3        1742          51          3%
  BC\#24                                Primary                                        22%                    1            1128         858          982          79          999                                                  \<1         495         21363         668         3%
  BC\#25                                Primary                                        10%                    0            1165         666          573          94          627                                                  12          474         14542         244         2%
  BC\#26                                Primary                                        10%                    0            1446         429          572          0           685                                                  230         510         5771          257         4%
  BC\#27                                Primary                                        14%                    2            880          4            452          94          415                                                  \<1         222         1505          299         17%
  BC\#28                                Primary                                        5%                     \<1          182          91           113          7           119                                                  6           80.3        1221          50          4%
  BC\#29                                Primary                                        9%                     \<1          656          530          469          32          532                                                  9           473         50360         255         1%
  BC\#30                                Primary                                        7%                     3            823          94           341          247         403                                                  34          244         9097          373         4%
  BC\#31                                Primary                                        4%                     0            345          166          216          0           161                                                  3           145         1085          79          7%
  BC\#32                                Primary                                        7%                     \<1          629          13           276          4           237                                                  19          194         1544          198         11%
  BC\#33                                Primary                                        9%                     \<1          725          397          428          232         549                                                  6           231         5414          144         3%
  BC\#34                                Primary                                        14%                    5            1061         245          557          0           457                                                  0           308         3866          176         4%
  BC\#35                                Primary                                        5%                     2            484          103          358          3           506                                                  50          185         23896         360         1%
  BC\#36                                Primary                                        13%                    0            1085         221          544          0           333                                                  13          347         1153          231         17%
  BC\#37                                Primary                                        4%                     0            376          193          149          \<1         144                                                  13          120         1081          289         21%
  BC\#38                                Primary                                        6%                     2            776          90           415          8           326                                                  12          281         4683          178         4%
  BC\#39                                Primary                                        14%                    0            961          5            731          83          691                                                  4           606         4829          152         3%
  ***Median***                                                                         ***7.9%***             ***0.7***    ***745***    ***193***    ***413***    ***5***     ***403***                                            ***10***    ***253***   ***5088***    ***244***   ***4%***
  **Cutaneous melanoma PDX**                                                                                                                                                                                                                                                          
  CM\#1                                 Metastasis                                     11%                    0            1725         2985         825          0           953                                                  83          1026        10386         1401        12%
  CM\#2                                 Metastasis                                     7%                     27           544          1391         426          768         360                                                  0           184         10696         315         3%
  CM\#3                                 Metastasis                                     4%                     1            282          257          180          0           122                                                  1           155         599           102         14%
  CM\#4                                 Primary                                        20%                    0            3306         784          1178         427         883                                                  38          836         9188          718         7%
  CM\#5                                 Metastasis                                     8%                     9            936          872          363          15          587                                                  0           289         5590          201         3%
  CM\#6                                 Metastasis                                     3%                     \<1          342          648          196          6           188                                                  5           236         960           23          2%
  CM\#7                                 Metastasis                                     1%                     2            176          382          83.6         2           135                                                  \<1         84.3        5962          37          1%
  CM\#8                                 Primary                                        10%                    9            4760         876          705          0           2230                                                 5           841         16732         239         1%
  CM\#9                                 Metastasis                                     1%                     0            118          284          61.6         20          125                                                  14          73.6        3704          24          1%
  CM\#10                                Primary                                        10%                    0            876          756          300          0           248                                                  279         285         387           126         25%
  CM\#11                                Metastasis                                     8%                     2            641          1102         427          0           355                                                  1           309         8837          266         3%
  CM\#12                                Primary                                        5%                     0            530          112          186          0           440                                                  0           423         683           26          4%
  CM\#13                                Metastasis                                     2%                     \<1          243          145          101          \<1         116                                                  1           82.2        466           31          6%
  ***Median***                                                                         ***7.1%***             ***0.9***    ***544***    ***756***    ***300***    ***0.8***   ***355***                                            ***1***     ***285***   ***5590***    ***126***   ***3%***
  **Renal cell carcinoma PDX**                                                                                                                                                                                                                                                        
  RCC\#1                                Primary                                        17%                    0            1179         569          1002         0           680                                                  2           473         19769         1513        7%
  RCC\#2                                Primary                                        12%                    0            3362         16           1929         0           1934                                                 0           3043        27096         54          0%
  RCC\#3                                Primary                                        27%                    0            5431         411          2376         0           1866                                                 0           1974        25792         211         1%
  RCC\#4                                Metastasis                                     11%                    120          2117         256          1430         4           1512                                                 0           1337        13968         89          1%
  RCC\#5                                Primary                                        16%                    5            2906         33           1942         3           1624                                                 0           2102        25817         87          0%
  RCC\#6                                Primary                                        1%                     1            341          2            125          2           157                                                  47          119         609           13          2%
  RCC\#7                                Primary                                        21%                    0            768          549          1908         0           1292                                                 0           1324        27232         157         1%
  RCC\#8                                Metastasis                                     17%                    1            842          410          778          0           466                                                  0           286         1756          930         35%
  RCC\#9                                Metastasis                                     13%                    17           2024         230          1258         3           827                                                  1           904         37839         55          0%
  RCC\#10                               Primary                                        11%                    0            2010         856          1359         0           1070                                                 2           672         37217         83          0%
  RCC\#11                               Primary                                        5%                     2            597          907          350          0           487                                                  0           253         5091          136         3%
  RCC\#12                               Metastasis                                     14%                    0            2546         257          1132         0           871                                                  0           1040        16952         61          0%
  RCC\#13                               Primary                                        21%                    0            4963         38           3466         0           3281                                                 0           3966        30645         155         1%
  RCC\#14                               Primary                                        6%                     330          1338         364          602          0           661                                                  2           343         26952         52          0%
  RCC\#15                               Primary                                        6%                     77           565          1036         293          0           368                                                  0           291         2210          59          3%
  ***Median***                                                                         ***12.9%***            ***1.2***    ***2010***   ***364***    ***1258***   ***0***     ***871***                                            ***0***     ***904***   ***25792***   ***87***    ***1%***
  **Lung carcinoma PDX**                                                                                                                                                                                                                                                              
  ***Small cell lung carcinoma***                                                                                                                                                                                                                                                     
  SCLC\#1                               Primary                                        8%                     0            1030         3            387          0           250                                                  0           196         419           43          9%
  SCLC\#2                               Primary                                        3%                     2            632          0            238          5           189                                                  0           185         1300          52          4%
  SCLC\#3                               Primary                                        4%                     4            591          0            259          1           232                                                  2           232         1117          49          4%
  SCLC\#4                               Primary                                        3%                     7            395          0            222          0           166                                                  0           162         1498          46          3%
  SCLC\#5                               Metastasis                                     2%                     0            309          1            153          0           160                                                  2           122         893           56          6%
  SCLC\#6                               Primary                                        7%                     2            670          9            221          471         208                                                  72          192         954           86          8%
  ***Median***                                                                         ***3.3%***             ***1.7***    ***612***    ***0***      ***230***    ***1***     ***198***                                            ***1***     ***189***   ***1035***    ***51***    ***5%***
  ***Non small cell lung carcinoma***                                                                                                                                                                                                                                                
  NSCLC\#1                              Primary                                        28%                    3            1969         61           941          2           1145                                                 14          637         18440         794         4%
  NSCLC\#2                              Primary                                        8%                     0            1270         0            611          0           511                                                  335         639         5911          98          2%
  NSCLC\#3                              Primary                                        22%                    95           1590         31           1438         124         961                                                  930         669         18346         429         2%
  NSCLC\#4                              Primary                                        5%                     2            686          5            339          4           212                                                  59          221         875           85          9%
  NSCLC\#5                              Primary                                        20%                    3            1363         667          1387         184         896                                                  3106        652         10612         688         6%
  ***Median***                                                                         ***20%***              ***2.7***    ***1363***   ***31***     ***941***    ***4***     ***896***                                            ***335***   ***639***   ***10612***   ***429***   ***4%***

Mouse cells encompass here a wide range of stromal cell types, including fibroblasts, inflammatory and immune cells, smooth muscle cells, and endothelial cells. We further focused on endothelial cells using expression of mouse *Pecam1*/*Cd31* and *Eng*/*Cd105* genes (hereinafter referred to as m*Cd31* and m*Cd105*, respectively) to evaluate their proportion within xenografts. *Vwf* gene encoding von Willebrand factor was also preliminary selected but not kept because of a lower expression rate in the mouse and human controls (Ct \> 30, data not shown).

As expected, all samples, collected from large xenografts without necrotic centre, expressed m*Cd31* and m*Cd105* genes. Nevertheless, m*Cd31* and m*Cd105* mRNA levels widely varied between the samples (Table [1](#T1){ref-type="table"}), but remained highly correlated to each other (*p* \< 10^-7^; Table [2](#T2){ref-type="table"}). Noteworthy, m*Cd31* and m*Cd105* expression levels were highly correlated with the proportion of mouse cells (Table [2](#T2){ref-type="table"}), suggesting that the relative amount of endothelial cells remains stable within diverse stromal cell populations, whatever the density of stroma component and the cancer type.

###### 

Relationships between mouse (m) and human (h) mRNA levels in the 150 human tumor xenografts

                      ***hCD31***   ***mCd31***       ***hCD105***   ***mCd105***      ***hVEGFR1***   ***mVegfr1***     ***hVEGFR2***   ***mVegfr2***     ***hVEGFA***     ***mVegfa***
  ------------------- ------------- ----------------- -------------- ----------------- --------------- ----------------- --------------- ----------------- ---------------- -----------------
  ***mCd31***         0.025^1^                                                                                                                                               
                      0.76^2^                                                                                                                                                
  ***hCD105***        0.043         0.121                                                                                                                                    
                      0.60          0.14                                                                                                                                     
  ***mCd105***        0.040         0.928             0.189                                                                                                                  
                      0.63          **\<0.0000001**   **0.02**                                                                                                               
  ***hVEGFR1***       0.065         0.022             -0.076         0.004                                                                                                   
                      0.43          0.79              0.35           0.96                                                                                                    
  ***mVegfr1***       0.076         0.851             0.305          0.877             0.006                                                                                 
                      0.35          **\<0.0000001**   **\<0.0002**   **\<0.0000001**   0.94                                                                                  
  ***hVEGFR2***       0.010         -0.029            0.232          -0.036            -0.036          0.070                                                                 
                      0.91          0.72              **\<0.005**    0.66              0.66            0.40                                                                  
  ***mVegfr2***       0.003         0.912             0.173          0.919             -0.017          0.858             -0.090                                              
                      0.98          **\<0.0000001**   **\<0.05**     **\<0.0000001**   0.83            **\<0.0000001**   0.27                                                
  ***hVEGFA***        0.095         0.477             0.319          0.563             0.090           0.726             0.131           0.517                               
                      0.25          **\<0.0000001**   **\<0.0002**   **\<0.0000001**   0.27            **\<0.0000001**   0.11            **\<0.0000001**                     
  ***mVegfa***        0.031         0.505             0.194          0.524             0.304           0.514             0.062           0.413             0.328             
                      0.70          **\<0.0000001**   **\<0.05**     **\<0.0000001**   **\<0.0002**    **\<0.0000001**   0.45            **\<0.0000001**   **\<0.00005**     
  **% mouse cells**   -0.016        0.828             0.113          0.865             0.154           0.715             -0.145          0.797             0.364            0.666
                      0.84          **\<0.0000001**   0.17           **\<0.0000001**   0.06            **\<0.0000001**   0.08            **\<0.0000001**   **\<0.000005**   **\<0.0000001**

Results, expressed as N-fold differences in target gene expression relative to the mouse and human *TBP* genes (both the mouse and human *TBP* transcripts) and termed "N*target*", were determined as Ntarget = 2^∆Ctsample^ , where the ∆Ct value of the sample was determined by subtracting the average Ct value of target gene (human or mouse) from the average Ct value of 'Total-*TBP'* gene). The N*target* values of the tumor samples were subsequently normalized such that the value for mRNA level was 1 when Ct=35. Target mRNA levels that were total absence or very low (Ct \> 38) in tumor samples were scored '0' for non expressed. As for calculation of % of mouse cells, specific mouse *Tbp* gene expression and the expression of both the mouse and the human *TBP* genes were studied by real-time qRT-PCR using the mouse *Tbp* as target gene and the 'Total-*TBP'* as endogenous RNA control. Results, expressed as N-fold differences in specific mouse *Tbp* gene expression (using mouse *Tbp* primers) relative to the sum of the mouse and the human *TBP* gene expression (using 'Total-*TBP'* primers), termed N*Mm-TBP*, are determined by theformula: N*Mm-TBP* = 2^DCtsample^. The DCt value of the sample is determined by subtracting the Ct value of the mouse *TBP* gene from the Ct value of the Total *TBP* gene. The N*Mm-TBP* values of the samples are subsequently normalized such that the median of N*Mm-TBP* values of 4 mouse tissues was 100. As *TBP* is a ubiquitously expressed housekeeping gene, showing similar expression in our human and mouse tissues (Ct=27 for 5 ng cDNA), the final result (normalized N*Mm-TBP* value) gives an estimate of the proportion of mouse cell content for a given xenograft. ^1^Spearman correlation coefficient, ^2^p value of Spearman rank correlation test, in bold when *p* is significant.

While numerous pro-angiogenic factors have been characterized, the VEGFA ligand has been identified as a predominant regulator of tumor angiogenesis and binds to VEGFR1 and VEGFR2 expressed on vascular endothelial cells. It mediates numerous changes within the tumor vasculature, including endothelial cell proliferation, migration, invasion, survival, chemotaxis of bone marrow-derived progenitor cells, vascular permeability and vasodilatation \[[@B1],[@B2]\]. VEGFA expression by cancer cells is up-regulated by altered expression of oncogenes, a variety of growth factors and also hypoxia \[[@B2]\].

Unsurprisingly, we observed high levels of mouse F*lt1/Vegfr1*, mouse *Kdr/Vegfr2* (hereby denominated m*Vegfr1* and m*Vegfr2*) and human *VEGFA (hVEGFA)* transcripts, which correlated all with m*Cd31* and m*Cd105* RNA levels (Table [2](#T2){ref-type="table"}). These strong positive correlations underline classical paracrine VEGFA-VEGFR1/2 signaling in tumorigenesis and crosstalk between the human ligand and mouse receptors. Expression of m*Vegfr1*, m*Vegfr2* and h*VEGFA* however varied widely in the different tumor types. RCC, glioblastoma and NSCLC xenografts showed transcript level median of these three genes at least 2 times higher than in the 5 other tumor xenograft types (Table [1](#T1){ref-type="table"}, Figure [1](#F1){ref-type="fig"}). According to the expression level of m*Cd105*, m*Cd31*, m*Vegfr1*, m*Vegfr2* and h*VEGFA* (Figure [1](#F1){ref-type="fig"})*,* the most angiogenic PDXs are then renal cell carcinoma, glioblastoma, and NSCLs, tumor types well-known to be the most angiogenic tumors in patients \[[@B11]\], underlying the interest of PDX models to mimic patient tumors.

![**Gene expression levels of mouse endothelial markers and*hVEGFA*in the 8 human tumor xenograft types.** Box-and-whisker diagrams showing the expression of mouse endothelial marker genes (*mCd31, mCd105, mVegfr1, mVegfr2)*, plot on left Y axis and *hVEGFA* gene plot on right Y axis. The box indicates the interquartile range, the centre horizontal line the median value and the black dots are outliers.](1471-2407-14-178-1){#F1}

Surprisingly, we observed also marked level of m*Vegfa* transcripts ranged from 50.7 (median in SCLC xenografts) to 429 (median in NSCLC xenografts). Individually, some xenografts showed more than 20% of the total *VEGFA* transcripts of mouse origin (Table [1](#T1){ref-type="table"}). While VEGFA production by cancer cells is commonly reported, significant *VEGFA* expression has been also observed by fibroblasts and immune cells that surround and invade the tumor mass \[[@B12]\]. As reported by others \[[@B13]\], great attention has to be paid to mouse stromal VEGFA when anti-VEGF agents displaying specific human activity are tested in xenograft preclinical models.

Angiogenesis and vasculogenesis, mediated by angiogenic factors such as VEGFA are commonly accepted to support tumor vasculature. Vascular mimicry (ability of tumor cells to form functional vessel-like networks, devoid of endothelial cells) and cancer stem cell transdifferentiation into tumor endothelial cells are also two mechanisms recently reported in different tumors, including melanoma, breast, renal, ovarian cancer and glioblastoma \[[@B14]-[@B18]\] in which tumor cells directly participate in vascular channels. The presence of tumor-derived endothelial cells (TDECs) is usually investigated through the detection of CD31+ and CD105+ tumor cells \[[@B15]-[@B18]\]. TDEC cells are generally rare events and their identification needs highly sensitive methods (flow cytometry or confocal microscopy). Likewise, another approach to improving the detection of TDEC is to enhance the TDEC frequency by implanting into mice cancer stem cell enriched population. This prior enrichment could be done by culturing cells as tumor spheres \[[@B19],[@B20]\] or by cell sorting for putative cancer stem cell markers \[[@B15],[@B21]\]. Only one recent publication attempted to immunostain human CD31 directly in 3 human tumor xenografts, with no preliminary step of TDEC or CSC enrichment \[[@B22]\]. This study did not detect human CD31 and led the authors to conclude that endothelial cells in human hepatocellular carcinoma xenografts are of mouse rather than human origin, but did not allow them to absolutely exclude this possibility. Consequently, we apply in our PDX panel the real-time qRT-PCR method, known for its very high sensitivity, using human-specific *PECAM1*/*CD31* (*hCD31*) and *ENG/CD105* (*hCD105*) to gain more insight into TDECs.

Surprisingly, we detected h*CD31* and h*CD105* transcripts in all types of PDXs, suggesting that TDECs can exist in virtually all types of cancer. The possibility of human endothelial marker signals due to very rare remaining human stroma cells can not be ignored, although the whole human stroma in tumor xenografts is reported to be eventually replaced by stroma of mouse origin \[[@B8],[@B23],[@B24]\]. But depending upon the types, the range of expression of h*CD31* and h*CD105* transcripts largely varied (Figure [2](#F2){ref-type="fig"}a-b). All tested samples of cutaneous melananoma and GBM highly expressed h*CD105* gene (N*Hs*-ENG \>100). Literature indeed reports a large expression of CD105, a member of the transforming growth factor beta receptor family, on normal and neoplastic cells of the melanocytic lineage, including melanoma cell lines, and an up-regulation in gene signature of aggressive cutaneous melanoma in patients \[[@B14]\]. Likewise, CD105 is highly expressed in glioblastoma but essentially absent in normal brain \[[@B21]\]. RCC xenografts displayed a great proportion of samples expressed high levels of h*CD31* or h*CD105*. These results fit with the literature that identified TDECs in patients mainly in glioblastoma and renal cancer \[[@B16],[@B21]\]. By contrast, SCLCs show very low levels of both h*CD31* and h*CD105* mRNAs. A striking point is that h*CD31* and h*CD105* RNA levels did not correlate to each others (Table [2](#T2){ref-type="table"}), even if their expression is analyzed for each cancer type (data not shown). It could be explained by different expression profiles for these 2 endothelial molecules: CD31 is considered as a pan-endothelial marker, whereas CD105 is a cell membrane glycoprotein predominantly expressed on cellular lineages within the vascular system, and over-expressed on proliferating endothelial cells \[[@B25]\]. These data underline that combination of markers is required to study the TDEC population.

![**Variations of human*hCD31*(a),*hCD105*(b),*hVEGFR1*(c) and*hVEGFR2*(d) gene expression within the 8 human tumor xenograft types.** Results are expressed for each cancer type as percent of PDX specimens showing normalized N*target* values in the following categories: no expression, 0 to 1, 1 to 10, 10 to 100 or more than 100.](1471-2407-14-178-2){#F2}

Initially, VEGFRs were thought to be expressed only on endothelial cells, but these receptors may also be expressed on tumor cells and play a role in tumor resistance to existing therapies \[[@B5]-[@B7]\]. The present species-specific real-time qRT-PCR assays combined with our series of 150 PDXs represents a powerful tool to obtain further insight into autocrine and paracrine VEGFA-VEGR1/2 signaling in tumorigenesis. We indeed observed human VEGFR expression in xenografts with a profile that varied widely according to tumor types (Table [1](#T1){ref-type="table"}, Figure [2](#F2){ref-type="fig"}c-d): High levels of h*VEGFR1* transcripts mainly observed in colon cancers and in NSCLCs; high levels of h*VEGFR2* transcripts in NSCLCs. Individually, 2 out of 5 NSCLC xenografts (i.e.: NSCLC\#3 and \#5) showed more h*VEGFR2* transcripts than m*Vegfr2* transcripts (Table [1](#T1){ref-type="table"}). Conversely, SCLCs showed low levels of h*VEGFR1* and h*VEGFR2* transcripts and CRCs showed very low levels of h*VEGFR2* transcripts (Absence in 89% of the 53 CRC xenografts). These results identified NSCLC as an attractive cancer type for anti-VEGFR2 treatment. Small-molecule inhibitors as Sunitinib and Sorafenib are oral multikinase inhibitors, including VEGFR2 among their targets. The development of antibodies that can selectively block VEGFR2 could potentially result in improved potency or tolerability \[[@B3]\].

Whereras m*Vegfr1* and m*Vegfr2* expressions were extremely correlated to mouse endothelial markers (*p* \< 10^-7^), human VEGFR profiles did not correlate highly with neither h*CD31* nor h*CD105*. Non exclusive hypotheses could explain this observation: i) human tumor cells expressing endothelial markers lead to VEGF- independent tumor vascularization with no expression of VEGFR1/2 \[[@B20]\]; ii) VEGFRs could be also expressed on carcinoma and participate to an essential autocrine/paracrine process for cancer cell proliferation and survival \[[@B1]\].

Collectively, VEGFA/VEGFR analyses suggest several autocrine and paracrine VEGFA-VEGFR1/2 signalings. In additional to the classical paracrine human tumoral VEGFA/mouse stromal VEGFR signalling, our data identified 3 others potential VEGFA-VEGFR signalings: a human cancer autocrine VEGFA/VEGFR signaling, an autocrine or paracrine mouse stromal VEGFA/VEGFR signaling, and a paracrine mouse stromal VEGFA/ human tumoral VEGFR signaling. It is noteworthy that the human cancer autocrine VEGFA/VEGFR signaling could occur intracellular, as well as by VEGFA secretion \[[@B6]\], limiting the quantity of extracellular VEGFA. Thus, VEGFR small-molecule inhibitors might be a more attractive therapy than VEGFA inhibitors which aim to sequestering free VEGFA.

To further investigate the potential value of species-specific PCR assays for *in vivo* evaluation of anti-angiogenesis therapy in PDX models, we analyzed in the same manner as described above, 2 NSCLC xenograft models after treatment with bevacizumab, a recombinant humanized monoclonal antibody to VEGF, approved for cancer therapy, including in NSCLC patients. These both models highly responded to one week-bevacizumab treatment in monotherapy: no tumor shrinkage but tumor stabilization throughout the experiment (Additional file [2](#S2){ref-type="supplementary-material"}: Figure S1).

As expected, the levels of m*Cd31,* m*Cd105,* m*Vegfr1* and m*Vegfr2* transcripts were significantly lower in the two bevacizumab-treated NSCLC xenografts as compared to matched non-treated xenografts (Table [3](#T3){ref-type="table"}). Indeed, even if bevacizumab is able to bind and inhibit human VEGFA but unable to neutralize murine VEGFA, VEGFA in these 2 xenografts is produced by human cancer cells rather than by mouse stroma cells. It is noteworthy that one of the two xenografts (NSCLC\#3) showed a significant upregulation of h*VEGFA* gene. More interestingly, the levels of h*CD31,* h*CD105,* h*VEGFR1* and h*VEGFR2* transcripts were not inferior in the two bevacizumab-treated NSCLC xenografts but on the contrary, h*CD31* was upregulated by 3 times (p \< 0.05 for NSCLC\#3) in both bevacizumab-treated xenografts. These data suggest that the mouse endothelial cells are more sensitive to anti-VEGFA therapy than human cells. Indeed, cancer cells are able to take advantage of autocrine intracellular VEGFA/VEGFR signalling \[[@B6]\] while bevacizumab is directed against free fraction of VEGFA. Furthermore, transdifferentiation of tumor cells into endothelial cells has been reported to be VEGF-independent but induced by HIF-1α \[[@B20]\]. Finally, bevacizumab induces hypoxia through mouse endothelial cells destruction, which may lead in turn to TDEC expansion. These latter results are of interest to apprehend molecular mechanisms of bevacizumab resistance.

###### 

Target mRNA levels in 2 NSCLC xenografts after bevacizumab treatment

                           **NSCLC\#3**  **NSCLC\#5**                                                                                                 
  ----------------------- -------------- ---------------------- ------------------------ ------------ ----------------------- ----------------------- ------------
  ***PECAM1/CD31*mRNA**    ***Human***   18.1 (7.34-43.1)       57.6 (31.8-64.2)         **\<0.05**      2.38 (0.00-9.21)     6.70 (2.41-17.1) NS      
                           ***Mouse***   863 (686-1790)         578 (483-847)            **\<0.05**     2 334 (1 538-4 363)   856 (699-980)           **\<0.05**
  ***ENG/CD105*mRNA**      ***Human***   29.1 (3.59-47.2)       38.2 (15.1-71.4)         NS             57.64 (38.8-90.86)    57.50 (47.2 - 84.4)     NS
                           ***Mouse***   619 (580-1098)         414 (328-619)            **\<0.05**      1 519 (1120-1813)    821 (610-860)           **\<0.05**
  ***FLT1/VEGFR1*mRNA**    ***Human***   59.6 (56.7-90.6)       88.9 (62.3-118)          NS              3.84 (0.00-24.8)     9.11 (3.87-20.3)        NS
                           ***Mouse***   589 (470-909)          274 (212-362)            **\<0.05**       938 (633-1163)      305 (216-344)           **\<0.05**
  ***KDR/VEGFR2*mRNA**     ***Human***   507 (361-622)          545 (488-643)            NS                220 (140-274)      574 (213-834)           NS
                           ***Mouse***   466 (386-800)          204 (196-298)            **\<0.05**      1 175 (698-1 211)    328 (316-349)           **\<0.05**
  ***VEGFA*mRNA**          ***Human***   20 503 (19162-24600)   32 160 (30 331-35 680)   **\<0.05**    11 984 (5 368-13 961)  12 235 (7 088-14 042)   NS
                           ***Mouse***   160 (119-495)          307 (184-614)            NS                262 (170-680)      267 (240-360)           NS

Results are expressed as normalized N-fold differences in target gene expression relative to the 'Total-TBP' expression. These N*target* values of the tumor samples were normalized such that the value for the 'basal mRNA level' (Ct = 35) was ^1^Target mRNA levels that were total absence or very low (Ct \> 38) in tumor samples were scored '0' for non expressed.

Median and range in () are given for each gene in the different experimental conditions. ^1^Mann Whitney Test; NS, not significant; in bold, significant.

Conclusions
===========

The screening of a large panel of xenografts established from various tumor types is appropriate to identify the human tumor types that are likely to benefit from a new targeted therapy, and next to identify predictive biomarkers for the response to this targeted therapy. Human tumor xenografted models, closely mimicking clinical situations in terms of biological features and response to treatment \[[@B8]\], will also provide the necessary experimental conditions to evaluate fundamental issues in cancer, including characteristics of metastasis, angiogenesis, and tumor-stroma interactions. The present approach combining species-specific real-time qRT-PCR assays with a large cohort of patient-derived xenografts identified tumor endothelial cells in the all 8 tumor types tested and also revealed a complex pattern of both stroma and tumoral and both autocrine and paracrine VEGFA-VEGFR1/2 signalings. These both findings should be taken into account when evaluating molecular mechanisms of resistance to tumor anti-angiogenic strategies.

Methods
=======

Patient-derived xenografts
--------------------------

Tumor xenografts have been established directly from patient tumors and were routinely passaged by subcutaneous engraftment in Crl:NU(Ico)-Foxn1^nu^ or CB17/Icr-Prkdc^scid^/IcrCrl \[[@B23],[@B24],[@B26]-[@B31]\] purchased from Charles River Laboratories (Les Arbresles, France), with protocol and animal housing in accordance with national regulation and international guidelines \[[@B32]\]. Xenografts were harvested here, after 5 to 12 passages into mice, when they reached around 2,000 mg in size.

Bevacizumab (Avastin, Roche) was given i.p. twice a week, one week, at 15 mg/kg in 0.9% NaCl. Omalizumab (Xolair, Novartis) is given as isotypic control. Lung carcinoma xenografts were transplanted into female 8-week-old Crl:NU(Ico)-Foxn1^nu^ mice. Mice with tumors of 60--200 mm^3^ were randomly assigned to control or treated groups. Tumor growth was evaluated by measurement of two perpendicular tumor diameters with a caliper twice a week. Individual tumor volumes were calculated: V = a × b^2^/2, a being the largest diameter, b the smallest. Mice were ethically sacrificed when the tumor volume reached 2 500 mm^3^ for control groups or at D29 and D50 after first injection of bevacizumab for NSCLC\#2 and NCSCLC\#3, respectively.

Real-time RT-PCR
----------------

RNA extraction, cDNA synthesis and PCR conditions were previously described \[[@B33]\]. The precise amount and quality of total RNA in each reaction mix are both difficult to assess. Therefore, transcripts of the *TBP* gene encoding the TATA box-binding protein (a component of the DNA-binding protein complex TFIID) were quantified as an endogenous RNA control. The endogenous *TBP* control was selected due to the moderate prevalence of its transcripts and the absence of known *TBP* retropseudogenes (retropseudogenes lead to coamplification of contaminating genomic DNA and thus interfere with RT-PCR, despite the use of primers in separate exons) \[[@B9]\].

Quantitative values were obtained from the cycle number (Ct value) (Perkin-Elmer Applied Biosystems, Foster City, CA), according to the manufacturer's manuals.

The gene primers (Additional file [1](#S1){ref-type="supplementary-material"}: Table S1) were chosen using the Oligo 6.0 program (National Biosciences, Plymouth, MN). The mouse and the human target genes primer pairs were selected to be unique when compared to the sequence of their respective orthologous gene. By contrast, a primer pair, referred as to 'Total-*TBP'* primer pair*,* was selected to amplify both the mouse and the human *TBP* genes. dbEST and nr databases were scanned to confirm the total gene specificity of the nucleotide sequences chosen for the primers and the absence of single nucleotide polymorphisms. To avoid amplification of contaminating genomic DNA, one of the two primers was always placed at the junction between two exons. Agarose gel electrophoresis was used to verify the specificity of PCR amplicons. For each human-specific primer pair validation, we performed no-template control (NTC), no-human-reverse-transcriptase control (human RT negative), mouse-reverse-transcriptase control (mouse RT positive from a pool of normal and tumoral mouse RNAs extracted from various tissues types) assays, which produced negligible signals (Ct \>40), suggesting that primer--dimer formation, genomic DNA contamination and cross species contamination effects were negligible. Same controls were realized for each mouse-specific primer pair.

Statistical analysis
--------------------

The distributions of mRNA levels were characterized by their median values and ranges. Relationships between mRNA levels of the different target genes were identified using nonparametric tests (GraphPad Prism 4.00, GraphPad Software, San Diego, CA).

Abbreviations
=============

CRC: Colorectal cancer; CSC: Cancer stem cell; GBM: Glioblastoma; NSCLC: Non small cell lung carcinoma; PDX: Patient-derived tumor xenograft; RCC: Renal cell carcinoma; SCLC: Small cell lung carcinoma; TDEC: Tumor-derived endothelial cell; mCd31: Mouse *Pecam1* gene encoding mouse CD31; mCd105: Mouse *Eng* gene encoding mouse CD105; mVegfr1: Mouse *Flt1* gene encoding mouse VEGFR1; mVegfr2: Mouse *Kdr* gene encoding mouse VEGFR2; hCD31: Human *PECAM1* gene encoding human CD31; hCD105: Human *ENG* gene encoding human CD105; hVEGFR1: Human *FLT1* gene encoding human VEGFR1; hVEGFR2: Human *KDR* gene encoding human VEGFR2.
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###### Additional file 2: Figure S1

Tumor growth curves of NSCLC\#3 and NSCLC\#5 xenografts as a function of time. Mice (at least 9 per group) were treated bevacizumab (•) at day 1 and 4; or not (o). Tumor volume was measured twice a week. Tumor growth was evaluated by plotting the mean of the RTV (relative tumor volume) ± SD per group over time after first treatment.
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